<- Go Home
IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Market Cap
$68.5M
Volume
339.3K
Cash and Equivalents
$36.9M
EBITDA
-$162.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$129.4M
Profit Margin
4827.30%
52 Week High
$22.50
52 Week Low
$0.92
Dividend
N/A
Price / Book Value
98.09
Price / Earnings
-0.35
Price / Tangible Book Value
98.09
Enterprise Value
-$39.6M
Enterprise Value / EBITDA
0.26
Operating Income
-$171.6M
Return on Equity
245.59%
Return on Assets
-36.78
Cash and Short Term Investments
$152.1M
Debt
$44.0M
Equity
$698.0K
Revenue
$2.7M
Unlevered FCF
-$75.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium